Anlotinib as Third-Line or Later Therapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Real-World Efficacy and Safety Outcomes
Yanwei Li, Shuang Li, Yang Li, Zhanyu Pan · 2026
Read Anlotinib as Third-Line or Later Therapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Real-World Efficacy and Safety Outcomes by Yanwei Li, Shuang Li, Yang Li, Zhanyu Pan (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13271921.txt.
Description
Yanwei Li is lead author of a 2026 retrospective real-world study of anlotinib as third-line or later therapy for recurrent or spread head and neck squamous cell carcinoma. Anlotinib is a multi-target drug that blocks blood vessel growth signals. Patients had already failed at least two prior drug regimens, leaving few options.
Among 68 patients treated at one centre between January 2021 and October 2023, fourteen had partial tumour shrinkage and 39 had stable disease, giving a response rate of 22.1 percent and disease control of 74.6 percent. Median time without progression was 6.3 months and median survival 8.4 months. Tumours with an inflamed immune profile, marked by a PD-L1 score and more killer T cells, responded better.
Catalog record
| CREATOR | Yanwei Li, Shuang Li, Yang Li, Zhanyu Pan |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 65240 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |